Royce & Associates LP Has $23.19 Million Stake in Artivion, Inc. (NYSE:AORT)

Royce & Associates LP lessened its stake in Artivion, Inc. (NYSE:AORT - Free Report) by 13.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 871,170 shares of the company's stock after selling 133,210 shares during the quarter. Royce & Associates LP owned about 2.08% of Artivion worth $23,191,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in shares of Artivion by 1.3% during the first quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company's stock valued at $56,388,000 after acquiring an additional 33,982 shares during the period. First Eagle Investment Management LLC boosted its stake in shares of Artivion by 4.9% in the 2nd quarter. First Eagle Investment Management LLC now owns 598,148 shares of the company's stock valued at $15,342,000 after purchasing an additional 27,906 shares during the last quarter. Tidal Investments LLC acquired a new stake in shares of Artivion during the 1st quarter worth approximately $257,000. Allspring Global Investments Holdings LLC raised its stake in shares of Artivion by 291.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company's stock worth $118,000 after buying an additional 4,154 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Artivion by 5.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 33,690 shares of the company's stock valued at $713,000 after buying an additional 1,634 shares during the period. 86.37% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Oppenheimer lifted their target price on shares of Artivion from $30.00 to $32.00 and gave the stock an "outperform" rating in a report on Friday, November 8th. JMP Securities started coverage on Artivion in a research note on Wednesday, October 23rd. They set an "outperform" rating and a $33.00 price objective for the company. Stifel Nicolaus increased their target price on Artivion from $28.00 to $30.00 and gave the company a "buy" rating in a research note on Friday, September 13th. Finally, Needham & Company LLC restated a "buy" rating and set a $30.00 target price on shares of Artivion in a research report on Friday, September 27th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $31.00.

Artivion Trading Down 1.3 %

Artivion stock traded down $0.34 during mid-day trading on Friday, hitting $26.65. 164,158 shares of the company's stock were exchanged, compared to its average volume of 225,000. The company's 50 day simple moving average is $26.34 and its 200-day simple moving average is $25.36. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $1.12 billion, a P/E ratio of -1,332.50 and a beta of 1.75. Artivion, Inc. has a fifty-two week low of $13.42 and a fifty-two week high of $30.00.

Insiders Place Their Bets

In other Artivion news, SVP Jean F. Holloway sold 3,167 shares of Artivion stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $26.55, for a total value of $84,083.85. Following the sale, the senior vice president now owns 161,932 shares of the company's stock, valued at $4,299,294.60. This trade represents a 1.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Amy Horton sold 12,430 shares of the business's stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total value of $325,417.40. Following the completion of the sale, the chief accounting officer now owns 139,989 shares in the company, valued at approximately $3,664,912.02. This trade represents a 8.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 8.10% of the company's stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.